title: Changes in numbers of epidermal cell adhesion molecules caused by oral cyclosporin in psoriasis.
abstract: OBJECTIVE
  To determine the effects of a three month course of low dose cyclosporin on the expression of epidermal cell adhesion molecules.
  
  
  METHODS
  Eighteen patients with psoriasis were treated for 12 weeks with either 2.5 or 5 mg/kg/day of oral cyclosporin. Biopsy specimens taken from skin before, during, and after cyclosporin treatment were stained immunohistochemically for CD 54 (ICAM-1), CD 29 (beta-1 integrins), and CD18 (beta-2 integrins).
  
  
  RESULTS
  There was a highly significant (p < 0.01) clinical response after 12 weeks of cyclosporin as assessed by the Psoriasis Area and Severity Index (PASI) score. The staining of CD 29 on keratinocytes of affected and unaffected psoriatic skin was not affected by cyclosporin. Epidermal CD54 was variably expressed in active psoriatic plaques and changed unpredictably after cyclosporin (p = NS). Staining for CD18 on large epidermal dendritic cells was reduced after cyclosporin (p < 0.02). The expression of CD18 by large epidermal dendritic cells during treatment correlated strongly with the PASI score at that time and one month after stopping cyclosporin (p < 0.02).
  
  
  CONCLUSIONS
  Persistence of epidermal staining for CD 54 in psoriasis is compatible with a good clinical response to cyclosporin. Residual staining for CD 18 on large epidermal dendritic cells may be a useful marker for early clinical relapse.
authors.affiliation: Department of Medicine, Royal Infirmary, Manchester.
authors.forename: B D
authors.initials: BD
authors.lastname: Edwards
authors.forename: S M
authors.initials: SM
authors.lastname: Andrew
authors.forename: J B
authors.initials: JB
authors.lastname: O'Driscoll
authors.forename: R J
authors.initials: RJ
authors.lastname: Chalmers
authors.forename: F W
authors.initials: FW
authors.lastname: Ballardie
authors.forename: A J
authors.initials: AJ
authors.lastname: Freemont
mesh_terms: D015703:Antigens, CD / Q000032:analysis*; D018821:CD18 Antigens; D015815:Cell Adhesion Molecules / Q000032:analysis*; D016572:Cyclosporine / Q000627:therapeutic use*; D006801:Humans; D019012:Integrin beta1; D018799:Intercellular Adhesion Molecule-1; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D012867:Skin / Q000276:immunology / Q000473:pathology
chemical_list: D015703:Antigens, CD; D018821:CD18 Antigens; D015815:Cell Adhesion Molecules; D019012:Integrin beta1; D018799:Intercellular Adhesion Molecule-1; D016572:Cyclosporine